Seven Structural Mistakes International Diagnostics Companies Make When Entering Canada

The most expensive assumption a US diagnostics company makes is that a Health Canada licence translates into a national commercial opportunity. It does not. Canada's provincial and territorial health systems each run their own evaluation, funding, and implementation machinery for diagnostics. There is no national reimbursement code for a precision diagnostic test. There is no unified adoption pathway. The structural divergence across provinces is architectural, not cosmetic.

Alberta, Ontario, Québec, and British Columbia each structure these two lanes differently: different committees own the evaluation decision, different organizations own the implementation build-out, and the observed timing patterns between the two vary dramatically. In some provinces, notice-to-go-live windows can be days to weeks once a decision is communicated publicly. In others, implementation lags persist even within pathways explicitly designed to synchronize evaluation and deployment.

A US company that builds one Canadian submission and one Canadian pricing model is building for a country that does not exist. And the cost of misreading which gate sequence you are entering is not measured in weeks. Based on observed decision latency patterns—where pre-publication assessment timelines are opaque, implementation requires site-level build-out, and budget escalation can compete against unrelated health system priorities—the planning error frequently extends by a year or more.

US companies tend to lead their Canadian value story with sensitivity, specificity, and variant-detection metrics. Those specifications matter. But they are not what Canadian decision-makers evaluate first. Provincial adoption decisions for precision diagnostics are oriented around a sequential decision test: What system problem does this solve? What workflow changes are required? What lab footprint can absorb it? Which budget envelope pays? How will utilization be governed?

If your value proposition does not address all five questions in the language the province uses, you are entering a queue that is not designed to process your dossier.

The evidence is in how provinces actually adopt. When Alberta approved its Cancer Biomarker Comprehensive DNA Panel, the operational bulletin framed the value around guideline-established biomarkers and consolidation of multi-step sequential testing into a single assay—not around genomic coverage breadth. When Alberta modernized its lung adenocarcinoma biomarker algorithm, it discontinued reflex ALK and ROS1 IHC and added reflex RNA NGS because sequential single-gene testing had become operationally unsustainable due to prolonged turnaround times and tissue exhaustion. The adoption trigger was operational sustainability.

In Québec, INESSS's evaluation of the liquid biopsy NGS panel for NSCLC explicitly tied clinical utility to enabling access to targeted therapies when tissue biopsy was infeasible or too slow, and to reducing care pathway delays. INESSS recommended the test as second-intention, retaining tissue biopsy as standard-of-practice, because the utility threshold was pathway impact within Québec's current drug and service context, not abstract analytic superiority.

Ontario's Comprehensive Cancer Biomarker Testing Program uses "Optional for 25/26" designations for certain biomarkers—a pipeline-managed expansion model where adoption is controlled by system readiness and designated-site capacity, not by whether the science supports the marker.

If your Canadian value proposition opens with "our panel detects 500 genes" instead of "our panel eliminates sequential testing workflows and reduces turnaround time by X days while operating within your existing lab infrastructure," you are speaking a language the decision system is not designed to hear.

In the US, companion diagnostics often benefit from coordinated commercial rollouts alongside their paired therapy. In Canada, diagnostic budgets and drug budgets sit in structurally different envelopes with different decision owners, different timelines, and different fiscal pressures. The fact that a therapy is funded does not mean the diagnostic required to access it is funded, operational, or available at the testing sites where patients present.

The structural disconnect runs deep. Drug budgets flow through centralized program mechanisms with explicit eligibility criteria. Diagnostic budgets are fragmented across hospital operating budgets, programmatic cancer funding, insured lab schedules, and global lab budgets—each with different decision owners and different fiscal pressures. The drug sponsor's clinical data alone does not satisfy the diagnostic budget holder's decision criteria.

Ontario's own cancer innovation literature has explicitly flagged the adversarial dynamic created when oncologists request biomarkers but laboratories are not funded to perform them. Québec has the most explicit companion diagnostic pathway of any province—INESSS operates a synchronized evaluation process designed to align test availability with drug listing timing. But even within this system, the companion test recommendation for RET fusion testing noted that the relevant multigene NGS panel had recently been added to the Répertoire and was still being implemented—a decision-to-availability gap within a system explicitly designed to prevent it.

Companies that assume their companion diagnostic will ride the drug's coattails into funded access are building a timeline based on a budget integration that does not exist in Canadian provincial architecture.

This is the mistake that most surprises US companies. In Canada, a broader genomic panel does not automatically equal more value. It can equal more risk—specifically, the risk that identifying more actionable targets will drive demand for drugs that are not on provincial formularies, creating pressure through exceptional access programs that provinces are structurally motivated to contain.

INESSS has been explicit about this. In its evaluation of the 52-gene Focus Panel for solid tumours, INESSS supported deployment for advanced NSCLC but cautioned against broader tumour-type use, warning that wider panels including genes without Québec-recognized clinical pertinence risk increasing requests for non-listed drugs through exceptional-access routes—including the Ministry's nécessité médicale particulière pathway and RAMQ patient d'exception mechanism. This is not theoretical caution. It is published payer logic: Québec treats broad genomic profiling as a drug-spillover risk management problem, not merely a diagnostic technology choice.

The sizing consequence: If your panel identifies twenty actionable targets but only four have funded therapies in the relevant province, you are not offering a twenty-target panel. You are offering a four-target panel with sixteen liabilities attached. Your Canadian market-sizing model needs to be built from the funded drug list backward, not from the genomic coverage forward.

Canadian provinces do not adopt a diagnostic and then leave ordering open. They adopt diagnostics with embedded utilization controls that function as market-size constraints. These controls are not afterthoughts; they are architectural features of the adoption decision itself.

Alberta's expansion of Oncotype DX to node-positive breast cancer restricted ordering to oncologists and designates, requiring documentation of specific clinical criteria on every requisition. Alberta's myeloid NGS panel rollout included explicit stewardship language about rationing use to clinically relevant settings. Even adopted tests are governed by algorithmic reflex rules, specialty-based ordering restrictions, and documentation requirements that limit who can order, for which patients, and under what clinical conditions.

Québec's liquid biopsy recommendation required creating a test-specific code, restricting eligible clinical indications via a standardized requisition, including a classification system for genomic alterations, adding prescriber-facing notes on analytic limitations, requiring ISO 15189 conformity, and mandating annual monitoring of utilization, turnaround time, volumetry, and costs. The adoption decision was inseparable from the governance framework that constrains its use.

US companies that model Canadian revenue based on prevalence multiplied by a unit price are modelling a market that does not exist. The real market is the prevalence that survives utilization governance, site-designation limits, and implementation capacity.

Provincial sequencing is a capital allocation decision, not a geographic preference. Each province presents a different risk-reward structure, and the right entry point depends on your diagnostic's specific evidence maturity, budget impact profile, infrastructure requirements, and therapy linkage. Companies that default to Ontario because of population size, or to Alberta because of perceived simplicity, often misread the structural dynamics and strand their evidence packages.

The critical variables that drive sequencing decisions are centralization, governance volatility, and entry logic—and they differ materially across provinces. A highly centralized province offers high leverage from a single adoption decision but concentrates risk if governance shifts mid-cycle. A fragmented province distributes risk but requires parallel engagement across multiple decision authorities. Governance volatility—organizational restructurings, committee transitions, intake pauses, ownership transfers—can suspend your investment thesis without resolution for the duration of the disruption.

As of early 2026, the governance landscape across Alberta, Ontario, Québec, and British Columbia each presents a distinct combination of these variables. Some provinces are undergoing major structural transitions that elevate risk. Others offer stable, structured processes but constrain the range of diagnostics they will consider. Still others present the largest addressable markets but require working across multiple decision authorities simultaneously. And some structurally limit direct industry engagement, requiring traction through internal clinical champions.

The key insight: your first province choice can strand your evidence package. Evidence framing, budget impact models, implementation footprints, and stakeholder alignment are province-specific assets, not portable templates. If you build for a highly centralized province and its governance shifts mid-cycle, you cannot easily redirect. Choosing wrong does not cost you one province—it costs you the full cycle of capital and evidence investment embedded in the attempt.

US companies often assume that Canada's Drug Agency (formerly CADTH) functions as a national gatekeeper for diagnostics—that a positive assessment opens provincial doors, and a negative one closes them. The operational reality is more fragmented, and understanding when CADTH matters and when it does not is essential to province-first strategy.

In many recent oncology laboratory adoptions across Alberta's system, CADTH is not cited as a required procedural step in the operational artifacts governing those adoptions. Alberta's Lab Formulary Committee and APL's rapid-HTA framework operationally function as the primary procedural gates in recent oncology lab adoptions.

In Québec, INESSS runs its own evaluation-to-Minister pathway. CADTH appears as a methodological and dissemination interface—INESSS states that the HTA portion of notices to the Minister is translated into English by CADTH as part of a formal collaboration—but this is an information-sharing arrangement, not a decision-right interface.

The strategic error is not ignoring CADTH. It is treating CADTH as a single national gate instead of one conditional input within province-specific machinery. Your strategy must be province-first, with CADTH positioned as a supporting asset where it provides leverage.